ACE2: Friend or Foe in Post-COVID-19 Neurodegeneration?

Area of Science:

• Neuroscience
• Biochemistry
• Virology

Background:

• Angiotensin-converting enzyme 2 (ACE2) is a key regulator in the renin-angiotensin system.
• ACE2 has diverse functions, including amino acid transport, cell adhesion, and signaling pathway involvement.
• ACE2 influences neurotransmitter systems within the brain.

Purpose of the Study:

• To investigate the role of temporary ACE2 inactivation by SARS-CoV-2 spike protein in Alzheimer-like neurodegeneration.
• To determine if ACE2 can serve as a biomarker or therapeutic target for neurodegenerative diseases linked to SARS-CoV-2.

Main Methods:

• Literature review and analysis of existing research on ACE2 function and SARS-CoV-2 interaction.
• Examination of studies investigating the impact of viral spike proteins on neurological pathways.
• Synthesis of data on ACE2 expression and its correlation with neurodegeneration.

Main Results:

• ACE2 is the primary receptor for SARS-CoV-2.
• Low ACE2 levels in the brain, coupled with SARS-CoV-2 infection, elevate the risk of neurodegenerative conditions.
• The SARS-CoV-2 spike protein's interaction with ACE2 may contribute to Alzheimer-like pathology.

Conclusions:

• Temporary inactivation of ACE2 by the SARS-CoV-2 spike protein is a potential factor in Alzheimer-like neurodegeneration.
• ACE2 presents a promising target for therapeutic interventions against SARS-CoV-2-induced neurological damage.
• Further research is warranted to fully elucidate ACE2's role as a biomarker and therapeutic target in neurodegeneration.